Eligible patients ( aged @-@ years ; Mayo Clinic Score -LSB- MCS -RSB- of @ of higher -LSB- or @ in USA -RSB- ; and disease extending @ cm or more from anal verge ) were randomised ( @:@:@ ) to one of two dose levels of subcutaneous etrolizumab ( @ mg at weeks @ , @ , and @ , with placebo at week @ ; or @ mg loading dose -LSB- LD -RSB- at week @ followed by @ mg at weeks @ , @ , and @ ) , or matching placebo .